Form 4: Suvretta Capital Boosts Benitec Biopharma Stake

Suvretta Capital Management and its affiliated funds have significantly increased their beneficial ownership in Benitec Biopharma Inc. through a $20 million stock purchase.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen (collectively, the Reporting Persons) have reported changes in their beneficial ownership of Benitec Biopharma Inc. common stock.
• Averill Master Fund, Ltd. purchased 730,370 shares of common stock at $13.50 per share on November 7, 2025.
• Averill Madison Master Fund, Ltd. purchased 751,111 shares of common stock at $13.50 per share on November 7, 2025.
• The total acquisition amounts to 1,481,481 shares of common stock, representing a total investment of approximately $19,999,993.50.
• Following these transactions, Averill Master Fund, Ltd. beneficially owns 9,538,175 shares indirectly, and Averill Madison Master Fund, Ltd. beneficially owns 1,819,812 shares indirectly.
• The purchases were made pursuant to a Securities Purchase Agreement dated November 5, 2025, between Benitec Biopharma Inc. and the Funds.
• The Reporting Persons are considered Directors by deputization, with Kishan Mehta, a portfolio manager of Suvretta Capital, serving on the Issuer's board of directors, and are also 10% owners of Benitec Biopharma Inc.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant equity investment by an existing major institutional shareholder and director, indicating strong confidence and providing substantial capital to the company.

Positives

• Significant institutional investment by a major shareholder and director, indicating strong confidence in the company's future.
• The purchase of 1,481,481 shares at $13.50 per share injects nearly $20 million in capital into Benitec Biopharma Inc.
• Increased beneficial ownership by a 10% owner and director suggests alignment of interests with other shareholders.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the significant investment by a major institutional shareholder and director implies a positive outlook on the company's future prospects.

Management Comments

• Aaron Cowen disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any indirect pecuniary interest therein.

Industry Context

This transaction reflects continued institutional interest and capital allocation within the biopharmaceutical sector, particularly for companies like Benitec Biopharma Inc. that may be in development stages or seeking to advance their pipelines. Large investments from existing significant shareholders can signal confidence in a company's strategic direction and potential for future growth, which is a common theme in the capital-intensive biotech industry.

Comparison to Industry Standards

• The investment by Suvretta Capital Management, a prominent hedge fund, into Benitec Biopharma Inc. is consistent with institutional investors increasing stakes in promising biopharma companies, especially those with potential for significant clinical or commercial milestones.
• While specific comparable companies or projects are not detailed in the filing, a nearly $20 million equity infusion from a major existing shareholder is a substantial vote of confidence, often seen in companies approaching critical development phases or market entry, similar to how funds like Perceptive Advisors or RA Capital Management might support their portfolio biotechs.

Related Party Transactions

• The purchases were made by entities (Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.) managed by Suvretta Capital Management, LLC, which is a 10% owner and has a representative (Kishan Mehta) serving on the board of directors of Benitec Biopharma Inc. Aaron Cowen, who may be deemed to control Suvretta Capital, is also a 10% owner and director. This constitutes a transaction with a significant related party.

Stakeholder Impact

• Shareholders: The significant investment by a major institutional shareholder and director could be perceived as a strong vote of confidence, potentially leading to increased investor interest and share price stability or appreciation.
• Company: The nearly $20 million capital infusion provides Benitec Biopharma Inc. with additional financial resources for its operations, research, and development, or other strategic initiatives.

Key Dates

Recommendation

The substantial investment of nearly $20 million by a major institutional shareholder and director, Suvretta Capital Management, signals strong conviction in Benitec Biopharma Inc.'s prospects. This capital infusion strengthens the company's financial position and aligns the interests of a significant stakeholder with other investors. Such a move by an informed insider often precedes positive developments or reflects an undervalued stock, making it a strong buy signal for seasoned investors.

Keywords

Benitec Biopharma, BNTC, Suvretta Capital Management, Institutional Investment, Stock Purchase, Beneficial Ownership, Biopharma, Equity Raise